Nothing Special   »   [go: up one dir, main page]

CY2012010I2 - Συσκευη παρατεταμενης αποδεσμευσης με βαση πολυμερες - Google Patents

Συσκευη παρατεταμενης αποδεσμευσης με βαση πολυμερες

Info

Publication number
CY2012010I2
CY2012010I2 CY2012010C CY2012010C CY2012010I2 CY 2012010 I2 CY2012010 I2 CY 2012010I2 CY 2012010 C CY2012010 C CY 2012010C CY 2012010 C CY2012010 C CY 2012010C CY 2012010 I2 CY2012010 I2 CY 2012010I2
Authority
CY
Cyprus
Prior art keywords
polymers
device based
release device
extended release
extended
Prior art date
Application number
CY2012010C
Other languages
Greek (el)
English (en)
Other versions
CY2012010I1 (el
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35393985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2012010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Publication of CY2012010I1 publication Critical patent/CY2012010I1/el
Publication of CY2012010I2 publication Critical patent/CY2012010I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Vending Machines For Individual Products (AREA)
  • Silicon Polymers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Ceramic Products (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY2012010C 2004-04-15 2012-04-26 Συσκευη παρατεταμενης αποδεσμευσης με βαση πολυμερες CY2012010I2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/011547 WO2005110425A1 (en) 2004-04-15 2004-04-15 Polymer-based sustained release device

Publications (2)

Publication Number Publication Date
CY2012010I1 CY2012010I1 (el) 2015-08-05
CY2012010I2 true CY2012010I2 (el) 2015-08-05

Family

ID=35393985

Family Applications (2)

Application Number Title Priority Date Filing Date
CY2012010C CY2012010I2 (el) 2004-04-15 2012-04-26 Συσκευη παρατεταμενης αποδεσμευσης με βαση πολυμερες
CY20151100373T CY1116337T1 (el) 2004-04-15 2015-04-23 Διαταξη σταθερης αποδεσμευσης πολυμερους βασης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100373T CY1116337T1 (el) 2004-04-15 2015-04-23 Διαταξη σταθερης αποδεσμευσης πολυμερους βασης

Country Status (25)

Country Link
US (7) US8617613B2 (sl)
EP (2) EP2409707B8 (sl)
JP (1) JP5030292B2 (sl)
KR (2) KR101040415B1 (sl)
CN (1) CN1968700A (sl)
AT (1) ATE531374T1 (sl)
AU (1) AU2004319756C1 (sl)
BR (1) BRPI0418702A (sl)
CA (1) CA2560981C (sl)
CY (2) CY2012010I2 (sl)
DE (1) DE122012000028I1 (sl)
DK (1) DK1734971T3 (sl)
EA (1) EA200601904A1 (sl)
ES (2) ES2375802T3 (sl)
FR (1) FR12C0029I1 (sl)
HK (2) HK1099693A1 (sl)
HR (2) HRP20110831T1 (sl)
IL (1) IL178589A0 (sl)
LU (1) LU91989I2 (sl)
MX (1) MXPA06011924A (sl)
NO (1) NO20065217L (sl)
PL (2) PL1734971T3 (sl)
PT (2) PT2409707E (sl)
SI (1) SI2409707T1 (sl)
WO (1) WO2005110425A1 (sl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CA2560981C (en) * 2004-04-15 2013-02-19 Steven G. Wright Polymer-based sustained release device
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
AU2006265814B2 (en) * 2005-06-30 2012-05-10 Ipsen Pharma S.A.S. GLP-1 pharmaceutical compositions
DK1971362T3 (en) 2005-08-19 2015-01-26 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
AU2008231093A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CN101657190B (zh) * 2007-04-19 2013-09-11 东亚制药株式会社 一种适用于对葡萄糖控制肽进行控释的可生物降解的微球组合物及其制剂
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and their uses
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
JP5744735B2 (ja) 2008-09-04 2015-07-08 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 非水性担体を用いた徐放性製剤
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201504215PA (en) 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN105769771B (zh) * 2014-12-25 2019-02-01 四川科伦药物研究院有限公司 一种艾塞那肽缓释微球组合物及其制备方法
PL3297653T3 (pl) 2015-05-22 2022-01-31 The Board Of Trustees Of The Leland Stanford Junior University Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
US20220184192A1 (en) * 2019-04-02 2022-06-16 Cytomatrix Limited A Composition for the Delivery of Biologically Active Agents and Uses Thereof
CA3180674A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US11930804B2 (en) 2020-05-21 2024-03-19 Florida Power & Light Company Avian streamer deterrent for electric power line support structures

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (sl) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (sl) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS57119318A (en) * 1981-01-16 1982-07-24 Minolta Camera Co Ltd Filter having special effect
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US4737437A (en) 1986-03-27 1988-04-12 East Shore Chemical Co. Light sensitive diazo compound, composition and method of making the composition
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5271945A (en) 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
JP2827287B2 (ja) 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
ATE99546T1 (de) 1989-05-01 1994-01-15 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekuelen.
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
AU6402490A (en) 1989-08-28 1991-04-08 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU2154892A (en) 1991-05-07 1992-12-21 Dynagen, Inc. A controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
WO1993017075A1 (en) 1992-02-28 1993-09-02 Collagen Corporation High concentration homogenized collagen compositions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
DE669128T1 (de) 1992-11-17 1996-03-14 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
PT686045E (pt) 1993-02-23 2001-04-30 Genentech Inc Estabilizacao por excipientes de polipeptidos tratados com solventes organicos
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
SI0729357T1 (sl) 1993-11-19 2005-06-30 Janssen Pharmaceutica N.V. Mikroinkapsulirani 1,2-benzazoli
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP2275089A1 (en) 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
JPH07196479A (ja) 1994-01-04 1995-08-01 Unitika Ltd マイクロカプセルの製造法
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
DE69625623T2 (de) 1996-01-31 2003-11-06 Sumitomo Bakelite Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von in Epoxyharz eingekapselter Halbleitervorrichtung
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
WO1997035563A2 (en) * 1996-03-28 1997-10-02 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
EP0942740B1 (en) 1996-12-06 2003-08-27 Amgen Inc., Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6268630B1 (en) * 1999-03-16 2001-07-31 Sandia Corporation Silicon-on-insulator field effect transistor with improved body ties for rad-hard applications
AU773556B2 (en) 1999-04-05 2004-05-27 Mannkind Corporation Methods for fine powder formation
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
JP4665141B2 (ja) * 2001-06-29 2011-04-06 富士通セミコンダクター株式会社 半導体装置とその製造方法
WO2003066585A2 (en) 2002-02-08 2003-08-14 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
AU2003284028B2 (en) 2002-10-17 2007-05-10 Alkermes, Inc. Sustained release profile modification
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US6887613B2 (en) 2002-12-04 2005-05-03 General Motors Corporation Corrosion resistant PEM fuel cell
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US6968927B2 (en) * 2003-10-10 2005-11-29 Brian Scura Bicycle force balancing mechanism with a brake arm actuation assembly and a pivot member for dual main brake cable segments
CA2560981C (en) 2004-04-15 2013-02-19 Steven G. Wright Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
AU2008231093A1 (en) 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process

Also Published As

Publication number Publication date
CN1968700A (zh) 2007-05-23
LU91989I9 (sl) 2019-01-03
PL1734971T3 (pl) 2012-08-31
CA2560981C (en) 2013-02-19
NO20065217L (no) 2006-11-14
EP1734971A4 (en) 2009-12-23
US20080125351A1 (en) 2008-05-29
JP2007532640A (ja) 2007-11-15
US20140088003A1 (en) 2014-03-27
CY2012010I1 (el) 2015-08-05
PT1734971E (pt) 2012-02-02
US20070166352A1 (en) 2007-07-19
AU2004319756A1 (en) 2005-11-24
MXPA06011924A (es) 2007-06-11
KR20100129799A (ko) 2010-12-09
LU91989I2 (fr) 2012-07-02
US20080119569A1 (en) 2008-05-22
AU2004319756B2 (en) 2010-08-05
KR20070011506A (ko) 2007-01-24
PL2409707T3 (pl) 2015-08-31
US7563871B2 (en) 2009-07-21
US8877252B2 (en) 2014-11-04
PT2409707E (pt) 2015-04-08
US9238076B2 (en) 2016-01-19
WO2005110425A1 (en) 2005-11-24
US20090247463A1 (en) 2009-10-01
ES2375802T3 (es) 2012-03-06
EP2409707A1 (en) 2012-01-25
JP5030292B2 (ja) 2012-09-19
ES2536235T3 (es) 2015-05-21
AU2004319756C1 (en) 2014-02-20
EP1734971A1 (en) 2006-12-27
SI2409707T1 (sl) 2015-07-31
US20080260847A1 (en) 2008-10-23
FR12C0029I1 (fr) 2012-06-15
BRPI0418702A (pt) 2007-09-11
US8617613B2 (en) 2013-12-31
US20130130977A1 (en) 2013-05-23
ATE531374T1 (de) 2011-11-15
EA200601904A1 (ru) 2007-02-27
DK1734971T3 (da) 2012-02-13
EP2409707B8 (en) 2015-05-06
HRP20150272T1 (hr) 2015-07-03
HK1166606A1 (en) 2012-11-02
CA2560981A1 (en) 2005-11-24
HRP20110831T1 (hr) 2012-01-31
DE122012000028I1 (de) 2012-07-12
KR101040415B1 (ko) 2011-06-09
IL178589A0 (en) 2007-02-11
HK1099693A1 (en) 2007-08-24
EP1734971B8 (en) 2012-02-29
EP2409707B1 (en) 2015-02-25
CY1116337T1 (el) 2017-02-08
EP1734971B1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
CY2012010I1 (el) Συσκευη παρατεταμενης αποδεσμευσης με βαση πολυμερες
DE602005023244D1 (de) Vorrichtungspaarbildung
DE602006001240D1 (de) Sicherheitsgurtvorrichtung
DE602006019672D1 (de) Sicherheitsgurtvorrichtung
DE602005016187D1 (de) Staubreduzierende Einrichtung
DE602005012730D1 (de) Lk-kommunikationsgerät
FI20060616A0 (fi) Laiteen tunnistusnumeroon perustuva nimipalvalu
DE602006005864D1 (de) Sicherheitsgurtvorrichtung
DE602005027897D1 (de) Polyhedrisch modifiziertes polymer
DE602007006629D1 (de) Fussgänger-airbag-vorrichtung
DE602005000381D1 (de) Sicherheitsgurtvorrichtung
DE602005024345D1 (de) Sicherheitsvorrichtung an Zweirädern
DE502005008418D1 (de) Bremsvorrichtung
DE602005010667D1 (de) Erfassungssignalübertragungsvorrichtung
DE502005001883D1 (de) Anschlussvorrichtung
SE0400032L (sv) Avkänningsanordning
DE602005002678D1 (de) Anschlussvorrichtung
DE502005001288D1 (de) Anhaltevorrichtung
DE502005006735D1 (de) Stelleinrichtung
DE502005008087D1 (de) Verbindungsvorrichtung
DE502004012222D1 (de) Fadenaufhol-Vorrichtung
DE602005011223D1 (de) Airbagvorrichtung
DE502005001290D1 (de) Verbindungsvorrichtung
DE602005012509D1 (de) Kegelspielvorrichtung
DE602005009445D1 (de) Gassackvorrichtung